Short answer
CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026 announced.
CRISPR Therapeutics AG 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Business highlights included alongside quarterly results
- Full financial details and operating updates available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- CASGEVY revenue $99 million, up 30% quarter-over-quarter and nearly sixfold year-over-year, validating accelerating commercial adoption
- More than 750 patients initiated CASGEVY treatment worldwide, with approvals expanding to younger children in additional markets
- CTX310 received two FDA RMAT designations, potentially enabling accelerated development, review, and approval pathways
- Cash, equivalents, and marketable securities $2,276.6 million, bolstered by $585.4 million convertible-note proceeds and supporting pipeline investment
- Net loss $111.4 million versus $106.4 million, while R&D increased to $71.9 million and collaboration expense declined to $41.3 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CRISPR Therapeutics AG 8-K filings
Get the next CRSP 8-K as it lands
Follow CRSP for push alerts, or ask the research agent what this filing means.